Dupilumab: Mechanism of action, clinical, and translational science by Marc R. McCann, Matthew P. Kosloski, Christine Xu, John D. Davis, Mohamed A. Kamal

Connect to this object online.

Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials by Matthew P. Kosloski, George D. Kalliolias, Christine R. Xu, Sivan Harel, Ching‐Ha Lai, Wenjun Zheng, John D. Davis, Mohamed A. Kamal

Connect to this object online.

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics by Mohamed A. Kamal, Robert Dingman, Claire Q. Wang, Ching‐Ha Lai, Manoj Rajadhyaksha, Michelle DeVeaux, Jamie M. Orengo, Allen Radin, John D. Davis

Connect to this object online.

Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis by Mohamed A. Kamal, John D. Davis, Pavel Kovalenko, Kamal Srinivasan, Eric L. Simpson, Takeshi Nakahara, Makoto Sugaya, Atsuyuki Igarashi, Marius Ardeleanu, Christine Xu, Kazuhiko Arima

Connect to this object online.

A drug‐disease model for predicting survival in an Ebola outbreak by Masood Khaksar Toroghi, Nidal Al‐Huniti, John D. Davis, A. Thomas DiCioccio, Ronda Rippley, Alina Baum, Christos A. Kyratsous, Sumathi Sivapalasingam, Joel Kantrowitz, Mohamed A. Kamal

Connect to this object online.

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials by Matthew P. Kosloski, Emma Guttman‐Yassky, Michael J. Cork, Margitta Worm, Dong‐Ho Nahm, Xiaoping Zhu, Marcella K. Ruddy, Sivan Harel, Mohamed A. Kamal, Hélène Goulaouic, Christine R. Xu, Elena Avetisova, John D. Davis, Michael C. Nivens, Arsalan Shabbir, Allen Radin

Connect to this object online.